Taibang Biologic Group is a leading fully integrated plasma-based biopharmaceutical company in China. The company’s core capabilities include plasma collection, and the manufacturing and commercialization of human plasma-based biopharmaceutical products. These products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. As the company focuses on its plasma business, Taibang have expanded its product pipeline to include non-plasma biopharmaceutical products and bio-medical device products to complement its market position and expand its base of users in the growing core plasma therapeutic business.
Location: China
Investors 2
| Date | Name | Website |
| - | Centurium ... | centurium.... |
| - | IDG Capita... | en.idgcapi... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 20.04.2021 | CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. China Biologic Produ... | BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "... | marketscre... |
| 04.06.2016 | China Biologic announces secondary offering of common stock;... | Premium US-based private equity Warburg Pincus agreed to sell 2.775 million common shares in China ... | dealstreet... |